Peter Galen
Principal investigator, leads HEMEX HEALTH INC.
MedtechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$15.3MFederal grants as PI21 awards
4Patents grantedLatest Sep 15, 2026
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
21 awards · $15.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Mar 27, 2025 | NIH | SBIR Phase II Affordable, quantitative, point-of-care microchip-electrophoresis for screening and treatment monitoring of sickle cell disease, thalassemias, and anemias | $991K | HEMEX HEALTH INC |
| Sep 16, 2024 | NIH | SBIR Phase I Using an Inclined Plane System to Triage TBI Patients | $332K | HEMEX HEALTH INC |
| Feb 23, 2024 | NIH | SBIR Phase II Affordable, quantitative, point-of-care microchip-electrophoresis for screening and treatment monitoring of sickle cell disease, thalassemias, and anemias | $995K | HEMEX HEALTH INC |
| Dec 12, 2023 | NIH | STTR Phase I RHODA: Rapid Hemoglobin-Oxygen Dissociation Assay | $296K | HEMEX HEALTH INC |
| Jun 28, 2023 | NIH | STTR Phase II Portable, affordable, quantitative microchip electrophoresis for hemoglobin A1C testing | $865K | HEMEX HEALTH INC |
| Mar 15, 2023 | NIH | SBIR Phase II Affordable, quantitative, point-of-care microchip-electrophoresis for screening and treatment monitoring of sickle cell disease, thalassemias, and anemias | $1.0M | HEMEX HEALTH INC |
| Mar 15, 2023 | NIH | SBIR Phase II Affordable, quantitative, point-of-care microchip-electrophoresis for screening and treatment monitoring of sickle cell disease, thalassemias, and anemias | $1.0M | HEMEX HEALTH INC |
| Jun 30, 2022 | NIH | STTR Phase II Portable, affordable, quantitative microchip electrophoresis for hemoglobin A1C testing | $865K | HEMEX HEALTH INC |
| Aug 31, 2021 | NIH | SBIR Phase II Rapid, Point of Care Diagnostic for Malaria, highly sensitive for P. vivax, with species differentiation | $828K | HEMEX HEALTH INC |
| Mar 24, 2021 | NIH | SBIR Phase I Using Multi-Spectral Imaging with Microchip Electrophoresis to Accurately Screen Newborns for Sickle Cell Disease | $257K | HEMEX HEALTH INC |
| Aug 6, 2020 | NIH | SBIR Phase II Rapid, Point of Care Diagnostic for Malaria, highly sensitive for P. vivax, with species differentiation | $840K | HEMEX HEALTH INC |
| Aug 6, 2020 | NIH | SBIR Phase II Rapid, Point of Care Diagnostic for Malaria, highly sensitive for P. vivax, with species differentiation | $1.7M | HEMEX HEALTH INC |
| Apr 5, 2020 | NIH | STTR Phase I Portable, affordable, quantitative microchip electrophoresis system for integrated anemia and hemoglobin variant testing | $225K | HEMEX HEALTH INC |
| Mar 25, 2020 | NIH | SBIR Phase II HLS-Affordable, quantitative microchip-electrophoresis for sickle cell disease screening | $750K | HEMEX HEALTH INC |
| Apr 11, 2019 | NIH | SBIR Phase II HLS-Affordable, quantitative microchip-electrophoresis for sickle cell disease screening | $750K | HEMEX HEALTH INC |
| Aug 24, 2018 | NIH | SBIR Phase II HLS-Affordable, quantitative microchip-electrophoresis for sickle cell disease screening | $225K | HEMEX HEALTH INC |
| Aug 21, 2018 | NIH | STTR Phase I Portable, affordable, quantitative microchip electrophoresis for hemoglobin A1C testing | $225K | HEMEX HEALTH INC |
| Feb 27, 2018 | NIH | SBIR Phase II HLS-Highly-Sensitive, One-minute, Portable Diagnostic for Malaria Elimination | $746K | HEMEX HEALTH INC |
| Mar 2, 2017 | NIH | SBIR Phase II HLS-Highly-Sensitive, One-minute, Portable Diagnostic for Malaria Elimination | $1.5M | HEMEX HEALTH INC |
| Mar 1, 2017 | NIH | SBIR Phase II HLS-Highly-Sensitive, One-minute, Portable Diagnostic for Malaria Elimination | $741K | HEMEX HEALTH INC |
| — | NIH | SBIR Phase I SBIR Phase 1 Diagnostics to enable malaria and neglected tropical diseases | $225K | HEMEX HEALTH INC |
5 patents as inventor
- US 11971384HEMEX HEALTH INCApr 30, 2024
- US 12372512HEMEX HEALTH INCJul 29, 2025
- US 12656310HEMEX HEALTH INCJun 16, 2026
- US 12736500HEMEX HEALTH INCSep 15, 2026
- US HEMEX HEALTH INC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#23
Awards as PI#21
Patents#89
Companies
- HEMEX HEALTH INCLeads (SEC Form D) · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.